KPV: Complete Research Guide & Chemical Profile

KPV is a naturally occurring tripeptide with the sequence Lys-Pro-Val (lysine-proline-valine), corresponding to the C-terminal residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH). Despite being the minimal active fragment of alpha-MSH, KPV retains potent anti-inflammatory activity through mechanisms that include NF-kB pathway inhibition, pro-inflammatory cytokine suppression, and modulation of immune cell function. KPV is recognized as a host defense peptide with immunomodulatory properties relevant to inflammatory bowel disease, dermatitis, and other chronic inflammatory conditions.

• Name: KPV (Lys-Pro-Val, alpha-MSH 11-13)
• Amino Acid Sequence: H-Lys-Pro-Val-OH
• Molecular Formula: C16H30N4O4
• Molecular Weight: 342.43 Da
• Isoelectric Point: ~9.7 (basic due to lysine)
• Parent Peptide: alpha-MSH (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, residues 11-13)
• Classification: Anti-inflammatory tripeptide, melanocortin-derived host defense peptide, immunomodulator
• D-isomer: KPdV (Lys-Pro-D-Val) — stereoisomer with comparable anti-inflammatory activity

KPV consists of three amino acids: L-lysine (a basic, positively charged residue), L-proline (a cyclic imino acid that introduces a rigid kink in the peptide backbone), and L-valine (a branched-chain hydrophobic residue). The proline residue at position 2 constrains the backbone dihedral angles, creating a distinctive molecular geometry that may be important for biological activity. The lysine epsilon-amino group provides a positive charge at physiological pH that contributes to electrostatic interactions with target proteins and cell surface components.

Alpha-MSH is a 13-amino-acid peptide derived from proopiomelanocortin (POMC) by post-translational processing. While the full-length alpha-MSH signals primarily through melanocortin receptors (MC-1R through MC-5R), systematic structure-activity studies have demonstrated that most of the anti-inflammatory properties of alpha-MSH are retained in the C-terminal tripeptide KPV. Elliott et al. (2004) showed that KPV elicits intracellular calcium signaling in keratinocytes at concentrations as low as 10^-15 M, operating through pathways that do not require cAMP elevation, suggesting a mechanism distinct from classical MC-1R signaling.

KPV exerts its anti-inflammatory effects primarily through inhibition of the nuclear factor kappa-B (NF-kB) signaling pathway, a master regulator of inflammatory gene expression. KPV suppresses NF-kB nuclear translocation and DNA binding activity, resulting in reduced transcription of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-8), adhesion molecules (ICAM-1), chemokines (MCP-1), and inflammatory mediators (iNOS, COX-2).

Luger and Brzoska (2007) provided comprehensive evidence that alpha-MSH and its C-terminal tripeptide KPV affect multiple inflammatory pathways including NF-kB activation, adhesion molecule expression, chemokine receptor modulation, and pro-inflammatory cytokine production. The anti-inflammatory mechanism appears to involve both direct effects on immune cells (macrophages, lymphocytes, dendritic cells) and indirect effects on resident tissue cells (epithelial cells, keratinocytes, fibroblasts). KPV may enter cells via the peptide transporter PepT1, bypassing the need for classical melanocortin receptor engagement.

KPV has been investigated in numerous preclinical models of inflammatory disease, with a particular focus on conditions affecting epithelial barrier tissues such as the gastrointestinal tract and skin.

• Inflammatory bowel disease: DSS-induced colitis models, NF-kB pathway modulation, intestinal epithelial barrier restoration
• Colitis-associated cancer: PepT1-mediated KPV delivery reduces tumorigenesis in murine CAC models (Viennois et al., 2016)
• Dermatitis: contact dermatitis, atopic dermatitis, cutaneous inflammation models
• Nanoparticle drug delivery: KPV as both therapeutic agent and targeting ligand for PepT1-mediated intestinal delivery systems
• Ocular inflammation: uveitis and ocular surface inflammatory models
• Arthritis: rheumatoid arthritis and joint inflammation models
• Wound healing: anti-inflammatory and tissue repair promotion in wound models
• Asthma: airway inflammation and allergic response modulation

The gastrointestinal tract represents the most actively investigated therapeutic application for KPV. In DSS-induced colitis models, KPV administration significantly improves body weight, colon length, and disease activity index while reducing levels of oxidative stress markers (MPO, NO, ROS) and inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). Zhang et al. (2024) developed PepT1-targeted nanoparticles co-assembling KPV with the immunosuppressant FK506, demonstrating enhanced therapeutic efficacy in both acute and chronic colitis models compared to either agent alone.

Viennois et al. (2016) demonstrated a critical role for PepT1 in colitis-associated cancer and showed that KPV, transported via PepT1, could prevent carcinogenesis in wild-type mice but not in PepT1-knockout mice. This finding established the PepT1 transporter as essential for KPV's anti-tumorigenic activity in the intestinal epithelium. Wu et al. (2019) further developed this concept by creating PLGA-KPV nanoparticles coated with montmorillonite and chitosan for colon-specific delivery, achieving targeted accumulation in inflamed tissues with retention up to 36 hours. Rodrigues et al. (2025) reviewed KPV as a host defense peptide for IBD treatment strategy, highlighting its role alongside other antimicrobial and immunomodulatory peptides.

As a tripeptide, KPV is a substrate for the intestinal peptide transporter 1 (PepT1/SLC15A1), a proton-coupled oligopeptide transporter expressed on the apical membrane of intestinal epithelial cells. PepT1 is normally expressed at low levels in the healthy colon but is significantly upregulated during inflammatory bowel disease, creating a disease-state-dependent transport mechanism that concentrates KPV precisely at sites of intestinal inflammation.

• PepT1 transport: active transport via proton-coupled oligopeptide transporter 1; disease-state upregulation in inflamed colon
• Oral stability: short peptide length confers moderate resistance to gastric degradation compared to larger peptides
• Systemic half-life: short; rapid clearance typical of tripeptides; local delivery strategies preferred
• Effective concentrations: anti-inflammatory activity observed at femtomolar to nanomolar range in vitro
• Nanoparticle delivery: PLGA, chitosan, and montmorillonite-based carriers enhance stability and colon-specific targeting
• Cellular uptake: enters cells via PepT1 and potentially other di-/tripeptide transporters; intracellular mechanism of action

KPV belongs to a family of melanocortin-derived peptides with anti-inflammatory properties. Gravina et al. (2023) reviewed the melanocortin system in inflammatory bowel diseases, establishing the therapeutic potential of multiple melanocortin peptides for IBD treatment.

• KPV (alpha-MSH 11-13): tripeptide, MW 342.43, NF-kB inhibition, PepT1 substrate, no melanogenesis, potent anti-inflammatory at very low concentrations
• KdPT (IL-1beta 193-195): derivative tripeptide (Lys-D-Pro-Thr), comparable anti-inflammatory potency to KPV, may act through overlapping pathways
• Alpha-MSH (full-length): 13 amino acids, MC-1R through MC-5R agonist, melanogenesis + anti-inflammatory, cAMP-dependent signaling
• ACTH (1-39): 39 amino acids, MC-2R preferring, steroidogenic + anti-inflammatory, historically used for IBD (clinical reports)
• Melanotan II: cyclic analog targeting MC-1R/MC-3R/MC-4R, tanning + appetite effects, not primarily anti-inflammatory
• ACTH (1-17): partial ACTH fragment, calcium signaling in keratinocytes, intermediate anti-inflammatory profile

• Lyophilized powder: store at -20°C; protect from moisture; stable for 24+ months
• Reconstitution: dissolve in sterile water, PBS, or saline; highly soluble due to ionic lysine residue
• Stock solutions: prepare at 10-100 mM in sterile water; aliquot and store at -20°C
• Working dilutions: prepare fresh in culture medium or buffer; stable at 2-8°C for 24-48 hours
• pH stability: stable across pH 3-8; lysine maintains solubility at physiological pH
• Avoid repeated freeze-thaw cycles; single-use aliquots recommended for consistent bioactivity

• RP-HPLC: primary purity assessment; >95% expected for research grade; short retention time typical of small hydrophilic peptides
• Mass spectrometry: ESI-MS or MALDI-TOF for molecular weight confirmation (expected 342.43 Da)
• Amino acid analysis: quantitative verification of Lys:Pro:Val in 1:1:1 ratio
• Peptide content: typically 70-85% by weight (adjusted for counterion, water, and salt content)
• Sequence verification: Edman degradation or MS/MS fragmentation confirms Lys-Pro-Val sequence
• Endotoxin: <1.0 EU/mg by LAL method for cell culture and in vivo applications
• Bioactivity: NF-kB reporter assay or TNF-alpha suppression in LPS-stimulated macrophages

KPV is an active area of research at the intersection of melanocortin biology, inflammatory bowel disease therapeutics, and peptide-based drug delivery. The convergence of KPV's anti-inflammatory mechanism with the disease-state upregulation of PepT1 in inflamed intestinal epithelium creates a compelling rationale for targeted oral peptide therapy. Advanced nanoparticle delivery systems incorporating KPV continue to be refined for improved colon-specific targeting and sustained release.

Current research challenges include optimizing oral delivery formulations for clinical translation, establishing pharmacokinetic parameters in larger animal models, and conducting dose-ranging studies that bridge preclinical efficacy to human therapeutic concentrations. The extremely low effective concentrations of KPV (femtomolar range in some in vitro systems) represent both an advantage (therapeutic window) and a challenge (precise dosing and bioanalytical quantification). Integration of KPV into combination approaches with conventional immunosuppressants via nanoparticle co-delivery represents a promising frontier for IBD management strategies.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: TP508 (Chrysalin): Research Guide & Chemical Profile → https://www.chemverify.com/learn/tp508-chrysalin-research-guide-chemical-profile
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism